CompletedPhase 2

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Japan12 participantsStarted 2010-07

Plain-language summary

The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET (Neuroendocrine Tumor) Exclusion Criteria: * Patients with poorly differentiated neuroendocrine cancer are not eligible

What they're measuring

Clinical Benefit Response Rate (CBR)

Timeframe: Up to 799 days of treatment

Trial details

NCT IDNCT01121562

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-07

Results submitted2012-07-01

View on ClinicalTrials.gov More Pancreatic Neuroendocrine Tumors trials